The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increased worldwide

Hepatic fibrosis is an important factor in morbidity and mortality due to liver failure, cardiovascular events, and metabolic disorders

Currently no approved treatment is available

This study aimed to explore the effect of empagliflozin versus pioglitazone and placebo on liver steatosis and fibrosis in patients with T2DM and NAFLD

Compared to placebo, empagliflozine improves the CAP score and liver stiffness measurement (LSM) in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Empagliflozin decreases LSM more effectively than pioglitazone

Body weight and abdominal fat area decrease with empagliflozin